Highlights*
- Fourth quarter net sales up 11% to
$186 million , with organic growth of 10%1. Full-year net sales up 6% to$652 million , a record level of annual revenue since the relaunch ofEnerpac Tool Group in 2019, with organic growth of 4%. - IT&S fourth quarter product sales up 11% and service sales up 9% organically year-over-year.
- Fourth quarter net earnings of
$24 million (13.1% of net sales), or$0.47 per diluted share, versus$28 million (16.8% of net sales), or$0.52 , in the prior year; adjusted diluted EPS of$0.53 versus$0.52 . - Full-year net earnings of
$90 million (13.7% of net sales), or$1.72 per diluted share, versus$93 million (15.0% of net sales), or$1.70 , in the prior year; adjusted diluted EPS of$1.87 versus$1.81 . - Fourth quarter adjusted EBITDA of
$42 million at a 22.6% margin; full-year adjusted EBITDA of$154 million at a 23.7% margin. - Full-year cash from operations of
$130 million , up 17%, and free cash flow of$120 million , up 30% year-over-year. Net debt to adjusted EBITDA of 0.1x at year-end fiscal 2026, with$81 million returned to shareholders through share repurchases in fiscal 2026. - Completed the acquisition of
SFE Group onOctober 28, 2026 , as described in a separate press release issued today.
*This press release contains financial measures in accordance with
“We closed fiscal 2026 with a strong fourth quarter, supported by broad-based product strength across the
| Fourth Quarter and Fiscal 2026 Results | ||||||||||||
| (US$ in millions, except per share) | ||||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||
| Gross Profit Margin | 47.0% | 50.1% | 49.2% | 50.5% | ||||||||
| Net Earnings | ||||||||||||
| Net Earnings % of Sales | 13.1% | 16.8% | 13.7% | 15.0% | ||||||||
| Diluted EPS | ||||||||||||
| Adjusted Diluted EPS* | ||||||||||||
| Adjusted EBITDA* | ||||||||||||
| Adjusted EBITDA Margin* | 22.6% | 26.5% | 23.7% | 24.9% | ||||||||
On an organic basis, fourth quarter sales increased 10%, with IT&S up 10% and Cortland Biomedical up 13%. For the full year, organic sales increased 4%, with IT&S up 3% and Cortland Biomedical up 23%.
In the fourth quarter, net earnings declined year-over-year, primarily due to mix, higher incentive compensation, and investments for future growth. For the full year, net earnings declined to
Cash Flow
| (US$ in millions) | Fiscal 2026 | Fiscal 2025 |
| Cash provided by operating activities | ||
| Capital expenditures | (10.6) | (19.3) |
| Free cash flow* | ||
Balance Sheet and Leverage
| (US$ in millions) | |||||||
| Cash Balance | |||||||
| Debt Balance | |||||||
| Net Debt | |||||||
| Net Debt to Adjusted EBITDA2 | 0.1x | 0.5x | 0.3x | ||||
Fiscal 2027 Outlook
“Our fiscal 2027 guidance includes approximately 10 months of
The Company is introducing its fiscal 2027 guidance:
| Metric | Fiscal 2027 Guidance |
| Organic Sales Growth1 | 4% to 6% |
| Adjusted EBITDA | |
| Adjusted Diluted EPS | |
This guidance is based on the Company’s key foreign exchange rate assumptions and assumes no substantial change to the current tariff or regulatory environment.
Conference Call Information
An investor conference call is scheduled for
Investor Day
The Company will host an Investor Day on
1Organic sales represent net sales excluding the impact of foreign exchange rates, acquisitions, and divestitures. A reconciliation of organic sales to comparable net sales is presented in the tables accompanying this release.
2Calculated in accordance with the terms of the Company’s
Safe Harbor Statement
Certain of the above comments represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In addition to statements with respect to guidance, the terms “outlook,” “may,” “should,” “could,” “anticipate,” “believe,” “estimate,” “expect,” “objective,” “plan,” “project” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to inherent risks and uncertainties that may cause actual results or events to differ materially from those contemplated by such forward-looking statements. The following is a list of factors, among others, that could cause actual results to differ materially from the forward-looking statements, general economic uncertainty; the impact of geopolitical activity, including the armed conflicts in the
Non-GAAP Financial Information
This press release contains financial measures that are not measures presented in conformity with GAAP. These non-GAAP measures include organic sales, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net earnings, adjusted diluted earnings per share, adjusted operating profit, segment adjusted operating profit and adjusted EBITDA, adjusted SG&A expense, free cash flow, and net debt. This press release includes reconciliations of non-GAAP measures to the most comparable GAAP measure, included in the tables attached to this press release or in footnotes to the tables included in this press release. Management believes the non-GAAP measures presented in this press release are commonly used financial measures for investors to evaluate Enerpac Tool Group’s operating performance and financial position with respect to the periods presented and, when read in conjunction with the condensed consolidated financial statements, present a useful tool to evaluate ongoing operations and provide investors with metrics they can use to evaluate aspects of the Company’s performance from period to period. In addition, these are some of the financial metrics management uses in internal evaluations of the overall performance of the Company’s business. Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results. In addition, these non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. Adjusted EBITDA and Adjusted diluted earnings per share anticipated for fiscal year 2027 is calculated in a manner consistent with the historical presentation of that measure in the accompanying tables. Because of the forward-looking nature of this estimate, it is impractical to present a quantitative reconciliation of this non-GAAP measure to the comparable GAAP measure, and accordingly no such GAAP measure for that period is being presented.
About
Contact:
Senior Director, Investor Relations
christian.audi@enerpac.com
| Condensed Consolidated Statements of Earnings | ||||||||||||
| (In millions, except per share amounts) | ||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||
| Three Months Ended | Twelve Months Ended | |||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Net sales | $ | 185.7 | $ | 167.5 | $ | 652.3 | $ | 616.9 | ||||
| Cost of products sold | 98.3 | 83.7 | 331.1 | 305.1 | ||||||||
| Gross profit | 87.4 | 83.8 | 321.2 | 311.8 | ||||||||
| Selling, general and administrative expenses | 51.4 | 42.0 | 182.4 | 166.8 | ||||||||
| Amortization of intangible assets | 1.6 | 2.0 | 6.3 | 5.6 | ||||||||
| Restructuring charges | - | - | 3.3 | 5.9 | ||||||||
| Operating profit | 34.4 | 39.8 | 129.2 | 133.5 | ||||||||
| Financing costs, net | 2.4 | 2.4 | 9.0 | 9.9 | ||||||||
| Other expense, net | 0.8 | 0.6 | 2.7 | 2.9 | ||||||||
| Earnings before income tax expense | 31.2 | 36.8 | 117.5 | 120.7 | ||||||||
| Income tax expense | 6.8 | 8.7 | 27.8 | 28.0 | ||||||||
| Net earnings | $ | 24.4 | $ | 28.1 | $ | 89.7 | $ | 92.7 | ||||
| Earnings per share | ||||||||||||
| Basic | $ | 0.48 | $ | 0.52 | $ | 1.73 | $ | 1.72 | ||||
| Diluted | 0.47 | 0.52 | 1.72 | 1.70 | ||||||||
| Weighted average common shares outstanding | ||||||||||||
| Basic | 51.2 | 53.5 | 51.8 | 54.0 | ||||||||
| Diluted | 51.5 | 53.9 | 52.2 | 54.5 | ||||||||
| Condensed Consolidated Balance Sheets | |||||||
| (In millions) | |||||||
| (Unaudited) | |||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 174.7 | $ | 151.6 | |||
| Accounts receivable, net | 113.0 | 106.1 | |||||
| Inventories, net | 70.7 | 78.8 | |||||
| Other current assets | 48.5 | 39.6 | |||||
| Total current assets | 406.9 | 376.1 | |||||
| Property, plant and equipment, net | 54.4 | 53.3 | |||||
| 289.7 | 289.8 | ||||||
| Other intangible assets, net | 43.0 | 46.9 | |||||
| Other long-term assets | 64.6 | 61.8 | |||||
| Total assets | $ | 858.6 | $ | 827.9 | |||
| Liabilities and Shareholders' Equity | |||||||
| Current liabilities | |||||||
| Current maturities of long-term debt | $ | 10.0 | $ | 7.5 | |||
| Trade accounts payable | 42.8 | 42.9 | |||||
| Accrued compensation and benefits | 32.7 | 28.1 | |||||
| Income taxes payable | 7.9 | 5.4 | |||||
| Other current liabilities | 55.5 | 53.2 | |||||
| Total current liabilities | 148.9 | 137.1 | |||||
| Long-term debt, net | 172.3 | 182.2 | |||||
| Deferred income taxes | 10.9 | 6.2 | |||||
| Pension and postretirement benefit liabilities | 5.8 | 7.1 | |||||
| Other long-term liabilities | 67.6 | 61.6 | |||||
| Total liabilities | 405.5 | 394.2 | |||||
| Shareholders' equity | |||||||
| Common stock | 10.2 | 10.6 | |||||
| Additional paid-in capital | 252.0 | 243.1 | |||||
| Retained earnings | 291.0 | 284.1 | |||||
| Accumulated other comprehensive loss | (100.1 | ) | (104.1 | ) | |||
| Stock held in trust | (5.4 | ) | (3.5 | ) | |||
| Deferred compensation liability | 5.4 | 3.5 | |||||
| Total shareholders' equity | 453.1 | 433.7 | |||||
| Total liabilities and shareholders' equity | $ | 858.6 | $ | 827.9 | |||
| Condensed Consolidated Statements of Cash Flows | |||||||
| (In millions) | |||||||
| (Unaudited) | |||||||
| Year Ended | |||||||
| 2026 | 2025 | ||||||
| Operating Activities | |||||||
| Cash provided by operating activities | $ | 130.2 | $ | 111.3 | |||
| Investing Activities | |||||||
| Capital expenditures | (10.6 | ) | (19.3 | ) | |||
| Cash paid for business acquisitions, net of cash acquired | - | (26.7 | ) | ||||
| Purchase of business assets | (2.0 | ) | - | ||||
| Cash used in investing activities | $ | (12.6 | ) | $ | (46.0 | ) | |
| Financing Activities | |||||||
| Principal repayments on term loan | (7.5 | ) | (5.0 | ) | |||
| Borrowings on revolving credit facility | 14.0 | 14.4 | |||||
| Principal repayments on revolving credit facility | (14.0 | ) | (14.4 | ) | |||
| Purchase of treasury shares | (81.1 | ) | (68.7 | ) | |||
| Stock options and taxes paid related to the net share settlement of equity awards | (3.1 | ) | (5.5 | ) | |||
| Payment of cash dividend | (2.1 | ) | (2.2 | ) | |||
| Other | (1.5 | ) | - | ||||
| Cash used in financing activities | $ | (95.3 | ) | $ | (81.4 | ) | |
| Effect of exchange rate changes on cash | 0.8 | 0.6 | |||||
| Net increase (decrease) from cash and cash equivalents | $ | 23.1 | $ | (15.5 | ) | ||
| Cash and cash equivalents - beginning of period | 151.6 | 167.1 | |||||
| Cash and cash equivalents - end of period | $ | 174.7 | $ | 151.6 | |||
| Supplemental Unaudited Data | |||||||||||||||||||||||||||||||
| Reconciliation of GAAP Measures to Non-GAAP Measures | |||||||||||||||||||||||||||||||
| (Dollars in millions) | |||||||||||||||||||||||||||||||
| Fiscal 2025 | Fiscal 2026 | ||||||||||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | TOTAL | Q1 | Q2 | Q3 | Q4 | TOTAL | ||||||||||||||||||||||
| $ | 140.1 | $ | 140.7 | $ | 153.4 | $ | 161.6 | $ | 595.8 | $ | 137.8 | $ | 148.7 | $ | 161.0 | $ | 179.0 | $ | 626.5 | ||||||||||||
| Other | 5.1 | 4.8 | 5.3 | 5.9 | 21.1 | 6.4 | 6.1 | 6.6 | 6.7 | 25.8 | |||||||||||||||||||||
| $ | 145.2 | $ | 145.5 | $ | 158.7 | $ | 167.5 | $ | 616.9 | $ | 144.2 | $ | 154.8 | $ | 167.6 | $ | 185.7 | $ | 652.3 | ||||||||||||
| % Net Sales Growth (Decline) Year over Year | |||||||||||||||||||||||||||||||
| 2 | % | 4 | % | 5 | % | 5 | % | 4 | % | -2 | % | 6 | % | 5 | % | 11 | % | 5 | % | ||||||||||||
| Other | 3 | % | 33 | % | 19 | % | 10 | % | 15 | % | 27 | % | 27 | % | 25 | % | 13 | % | 23 | % | |||||||||||
| 2 | % | 5 | % | 6 | % | 6 | % | 5 | % | -1 | % | 6 | % | 6 | % | 11 | % | 6 | % | ||||||||||||
| Adjusted Selling, general and administrative expenses | |||||||||||||||||||||||||||||||
| Selling, general and administrative expenses | $ | 42.4 | $ | 41.5 | $ | 41.1 | $ | 42.0 | $ | 166.8 | $ | 43.1 | $ | 42.0 | $ | 45.8 | $ | 51.4 | $ | 182.4 | |||||||||||
| M&A charges (1) | (0.2 | ) | (0.3 | ) | (0.7 | ) | (0.3 | ) | (1.4 | ) | (0.1 | ) | (1.1 | ) | (1.6 | ) | (4.1 | ) | (6.9 | ) | |||||||||||
| Adjusted Selling, general and administrative expenses | $ | 42.2 | $ | 41.2 | $ | 40.4 | $ | 41.8 | $ | 165.5 | $ | 43.0 | $ | 40.9 | $ | 44.2 | $ | 47.3 | $ | 175.5 | |||||||||||
| Adjusted Selling, general and administrative expenses % | |||||||||||||||||||||||||||||||
| 29.0 | % | 28.3 | % | 25.5 | % | 24.9 | % | 26.8 | % | 29.8 | % | 26.4 | % | 26.4 | % | 25.5 | % | 26.9 | % | ||||||||||||
| Adjusted Operating profit | |||||||||||||||||||||||||||||||
| Operating profit | $ | 31.1 | $ | 30.8 | $ | 31.7 | $ | 39.8 | $ | 133.5 | $ | 28.5 | $ | 25.0 | $ | 41.3 | $ | 34.4 | $ | 129.2 | |||||||||||
| Restructuring charges | - | - | 5.9 | - | 5.9 | - | 3.3 | - | - | 3.3 | |||||||||||||||||||||
| M&A charges | 0.2 | 0.3 | 0.7 | 0.3 | 1.4 | 0.1 | 1.1 | 1.6 | 4.1 | 6.9 | |||||||||||||||||||||
| Adjusted Operating profit | $ | 31.3 | $ | 31.1 | $ | 38.3 | $ | 40.1 | $ | 140.8 | $ | 28.6 | $ | 29.4 | $ | 42.9 | $ | 38.5 | $ | 139.4 | |||||||||||
| Adjusted Operating profit by Segment | |||||||||||||||||||||||||||||||
| $ | 38.1 | $ | 38.8 | $ | 42.9 | $ | 47.0 | $ | 166.8 | $ | 35.8 | $ | 34.8 | $ | 48.7 | $ | 48.0 | $ | 167.3 | ||||||||||||
| Other | 1.3 | 1.3 | 2.1 | 1.4 | 6.1 | 2.2 | 1.6 | 2.1 | 1.4 | 7.3 | |||||||||||||||||||||
| (8.1 | ) | (9.0 | ) | (6.7 | ) | (8.3 | ) | (32.1 | ) | (9.4 | ) | (7.0 | ) | (7.9 | ) | (10.9 | ) | (35.2 | ) | ||||||||||||
| Adjusted operating profit | $ | 31.3 | $ | 31.1 | $ | 38.3 | $ | 40.1 | $ | 140.8 | $ | 28.6 | $ | 29.4 | $ | 42.9 | $ | 38.5 | $ | 139.4 | |||||||||||
| Adjusted Operating profit % | |||||||||||||||||||||||||||||||
| 27.2 | % | 27.5 | % | 27.9 | % | 29.1 | % | 28.0 | % | 25.9 | % | 23.4 | % | 30.3 | % | 26.8 | % | 26.7 | % | ||||||||||||
| Other | 26.1 | % | 27.0 | % | 39.4 | % | 23.0 | % | 28.8 | % | 34.3 | % | 26.1 | % | 31.5 | % | 21.0 | % | 28.2 | % | |||||||||||
| Adjusted Operating Profit % | 21.5 | % | 21.4 | % | 24.1 | % | 24.0 | % | 22.8 | % | 19.8 | % | 19.0 | % | 25.6 | % | 20.7 | % | 21.4 | % | |||||||||||
| EBITDA (2) | |||||||||||||||||||||||||||||||
| Net earnings | $ | 21.7 | $ | 20.9 | $ | 22.0 | $ | 28.1 | $ | 92.7 | $ | 19.1 | $ | 16.3 | $ | 29.8 | $ | 24.4 | $ | 89.7 | |||||||||||
| Financing costs, net | 2.8 | 2.4 | 2.4 | 2.4 | 9.9 | 2.3 | 2.1 | 2.3 | 2.4 | 9.0 | |||||||||||||||||||||
| Income tax expense | 6.2 | 6.8 | 6.3 | 8.7 | 28.0 | 6.4 | 5.8 | 8.9 | 6.8 | 27.8 | |||||||||||||||||||||
| Depreciation & amortization | 3.5 | 3.5 | 3.7 | 5.0 | 15.7 | 4.4 | 4.3 | 4.3 | 4.3 | 17.5 | |||||||||||||||||||||
| EBITDA | $ | 34.2 | $ | 33.5 | $ | 34.5 | $ | 44.2 | $ | 146.3 | $ | 32.3 | $ | 28.6 | $ | 45.3 | $ | 37.9 | $ | 144.0 | |||||||||||
| Adjusted EBITDA (2) | |||||||||||||||||||||||||||||||
| EBITDA | $ | 34.2 | $ | 33.5 | $ | 34.5 | $ | 44.2 | $ | 146.3 | $ | 32.3 | $ | 28.6 | $ | 45.3 | $ | 37.9 | $ | 144.0 | |||||||||||
| Restructuring charges | - | - | 5.9 | - | 5.9 | - | 3.3 | - | - | 3.3 | |||||||||||||||||||||
| M&A charges | 0.2 | 0.3 | 0.7 | 0.3 | 1.4 | 0.1 | 1.1 | 1.6 | 4.1 | 6.9 | |||||||||||||||||||||
| Adjusted EBITDA (2) | $ | 34.3 | $ | 33.8 | $ | 41.0 | $ | 44.5 | $ | 153.6 | $ | 32.4 | $ | 33.0 | $ | 46.9 | $ | 42.1 | $ | 154.3 | |||||||||||
| Adjusted EBITDA (2) by Segment | |||||||||||||||||||||||||||||||
| $ | 40.8 | $ | 41.3 | $ | 45.3 | $ | 50.8 | $ | 178.2 | $ | 38.9 | $ | 38.0 | $ | 51.9 | $ | 51.1 | $ | 179.9 | ||||||||||||
| Other | 1.5 | 1.5 | 2.3 | 1.6 | 6.9 | 2.5 | 1.8 | 2.3 | 1.6 | 8.1 | |||||||||||||||||||||
| (8.0 | ) | (9.0 | ) | (6.6 | ) | (7.9 | ) | (31.5 | ) | (9.0 | ) | (6.8 | ) | (7.3 | ) | (10.6 | ) | (33.7 | ) | ||||||||||||
| Adjusted EBITDA (2) | $ | 34.3 | $ | 33.8 | $ | 41.0 | $ | 44.5 | $ | 153.6 | $ | 32.4 | $ | 33.0 | $ | 46.9 | $ | 42.1 | $ | 154.3 | |||||||||||
| Adjusted EBITDA % (2) | |||||||||||||||||||||||||||||||
| 29.1 | % | 29.4 | % | 29.5 | % | 31.4 | % | 29.9 | % | 28.2 | % | 25.5 | % | 32.2 | % | 28.5 | % | 28.7 | % | ||||||||||||
| Other | 30.5 | % | 31.7 | % | 43.7 | % | 26.7 | % | 33.0 | % | 38.2 | % | 29.5 | % | 34.4 | % | 23.7 | % | 31.4 | % | |||||||||||
| Adjusted EBITDA % (2) | 23.6 | % | 23.2 | % | 25.9 | % | 26.5 | % | 24.9 | % | 22.4 | % | 21.3 | % | 28.0 | % | 22.6 | % | 23.7 | % | |||||||||||
| Notes: | |||||||||||||||||||||||||||||||
| (1) Minimal amounts of M&A Charges were recorded in cost of products sold in Q2 and Q4 Fiscal 2026 and Q2 Fiscal 2025 | |||||||||||||||||||||||||||||||
| (2) EBITDA represents net earnings before financing costs, net, income tax expense, and depreciation & amortization. Neither EBITDA nor adjusted EBITDA are calculated based upon generally accepted accounting principles ("GAAP"). The amounts included in the EBITDA and adjusted EBITDA calculation, however, are derived from amounts included in the Condensed Consolidated Statements of Earnings. EBITDA and adjusted EBITDA should not be considered as alternatives to net earnings, operating profit or operating cash flows. The Company has presented EBITDA and adjusted EBITDA because it regularly reviews these performance measures. In addition, EBITDA and adjusted EBITDA are used by many of our investors and lenders, and are presented as a convenience to them. The EBITDA and adjusted EBITDA measures presented may not always be comparable to similarly titled measures reported by other companies due to differences in the components of the calculation. | |||||||||||||||||||||||||||||||
| For all reconciliations of GAAP measures to Non-GAAP measures, the summation of the individual components may not equal the total due to rounding. | |||||||||||||||||||||||||||||||
| Supplemental Unaudited Data | ||||||||||||||||||||||||||
| Reconciliation of GAAP Measures to Non-GAAP Measures (Continued) | ||||||||||||||||||||||||||
| (Dollars in millions) | ||||||||||||||||||||||||||
| Fiscal 2025 | Fiscal 2026 | |||||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | YTD | Q1 | Q2 | Q3 | Q4 | YTD | |||||||||||||||||
| $ | 140.1 | $ | 140.7 | $ | 153.4 | $ | 161.6 | $ | 595.8 | $ | 137.8 | $ | 148.7 | $ | 161.0 | $ | 179.0 | $ | 626.5 | |||||||
| Other | 5.1 | 4.8 | 5.3 | 5.9 | 21.1 | 6.4 | 6.1 | 6.6 | 6.7 | 25.8 | ||||||||||||||||
| $ | 145.2 | $ | 145.5 | $ | 158.7 | $ | 167.5 | $ | 616.9 | $ | 144.2 | $ | 154.8 | $ | 167.6 | $ | 185.7 | $ | 652.3 | |||||||
| Adjustment: Fx Impact on | ||||||||||||||||||||||||||
| $ | 2.5 | $ | 6.1 | $ | 3.7 | $ | 0.6 | $ | 12.9 | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||
| Other | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||
| $ | 2.5 | $ | 6.1 | $ | 3.7 | $ | 0.6 | $ | 12.9 | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||
| Organic Sales by Segment (3) | ||||||||||||||||||||||||||
| $ | 142.6 | $ | 146.8 | $ | 157.1 | $ | 162.2 | $ | 608.7 | $ | 137.8 | $ | 148.7 | $ | 161.0 | $ | 179.0 | $ | 626.5 | |||||||
| Other | 5.1 | 4.8 | 5.3 | 5.9 | 21.1 | 6.4 | 6.1 | 6.6 | 6.7 | 25.8 | ||||||||||||||||
| $ | 147.7 | $ | 151.6 | $ | 162.4 | $ | 168.1 | $ | 629.8 | $ | 144.2 | $ | 154.8 | $ | 167.6 | $ | 185.7 | $ | 652.3 | |||||||
| Organic Sales Growth (Decline) % (3) | ||||||||||||||||||||||||||
| (3 | %) | 1 | % | 2 | % | 10 | % | 3 | % | |||||||||||||||||
| Other | 27 | % | 27 | % | 25 | % | 13 | % | 23 | % | ||||||||||||||||
| (2 | %) | 2 | % | 3 | % | 10 | % | 4 | % | |||||||||||||||||
| $ | 106.1 | $ | 113.9 | $ | 124.3 | $ | 134.7 | $ | 479.0 | $ | 112.1 | $ | 125.3 | $ | 133.6 | $ | 149.3 | $ | 520.3 | |||||||
| 34.0 | 26.8 | 29.1 | 26.9 | 116.8 | 25.7 | 23.4 | 27.4 | 29.7 | 106.2 | |||||||||||||||||
| $ | 140.1 | $ | 140.7 | $ | 153.4 | $ | 161.6 | $ | 595.8 | $ | 137.8 | $ | 148.7 | $ | 161.0 | $ | 179.0 | $ | 626.5 | |||||||
| Adjustment: Fx Impact on | ||||||||||||||||||||||||||
| $ | 1.7 | $ | 4.8 | $ | 2.8 | $ | 0.3 | $ | 9.7 | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||
| 0.8 | 1.3 | 0.9 | 0.3 | 3.3 | - | - | - | - | - | |||||||||||||||||
| $ | 2.5 | $ | 6.1 | $ | 3.7 | $ | 0.6 | $ | 12.9 | $ | - | $ | - | $ | - | $ | - | $ | - | |||||||
| $ | 107.8 | $ | 118.7 | $ | 127.1 | $ | 135.0 | $ | 488.7 | $ | 112.1 | $ | 125.3 | $ | 133.6 | $ | 149.3 | $ | 520.3 | |||||||
| 34.8 | 28.1 | 30.0 | 27.2 | 120.1 | 25.7 | 23.4 | 27.4 | 29.7 | 106.2 | |||||||||||||||||
| $ | 142.6 | $ | 146.8 | $ | 157.1 | $ | 162.2 | $ | 608.7 | $ | 137.8 | $ | 148.7 | $ | 161.0 | $ | 179.0 | $ | 626.5 | |||||||
| Organic Sales Growth (Decline) % (3) | ||||||||||||||||||||||||||
| 4 | % | 6 | % | 5 | % | 11 | % | 6 | % | |||||||||||||||||
| (26 | %) | (17 | %) | (8 | %) | 9 | % | (12 | %) | |||||||||||||||||
| (3 | %) | 1 | % | 2 | % | 10 | % | 3 | % | |||||||||||||||||
| Notes continued: | ||||||||||||||||||||||||||
| (3) Organic Sales is defined as sales excluding the impact to foreign currency changes and the impact from recent acquisitions and divestitures to net sales. | ||||||||||||||||||||||||||
| For all reconciliations of GAAP measures to Non-GAAP measures, the summation of the individual components may not equal the total due to rounding. | ||||||||||||||||||||||||||
| Supplemental Unaudited Data | |||||||||||||||||||||||||||||||
| Reconciliation of GAAP Measures to Non-GAAP Measures (Continued) | |||||||||||||||||||||||||||||||
| (In millions, except per share amounts) | |||||||||||||||||||||||||||||||
| Fiscal 2025 | Fiscal 2026 | ||||||||||||||||||||||||||||||
| Q1 | Q2 | Q3 | Q4 | TOTAL | Q1 | Q2 | Q3 | Q4 | TOTAL | ||||||||||||||||||||||
| Adjusted Earnings (4) | |||||||||||||||||||||||||||||||
| Net Earnings | $ | 21.7 | $ | 20.9 | $ | 22.0 | $ | 28.1 | $ | 92.7 | $ | 19.1 | $ | 16.3 | $ | 29.8 | $ | 24.4 | $ | 89.7 | |||||||||||
| Restructuring charges | - | - | 5.9 | - | 5.9 | - | 3.3 | - | - | 3.3 | |||||||||||||||||||||
| M&A charges | 0.2 | 0.3 | 0.7 | 0.3 | 1.4 | 0.1 | 1.1 | 1.6 | 4.1 | 6.9 | |||||||||||||||||||||
| Net tax effect of reconciling items above | (0.0 | ) | 0.0 | (0.9 | ) | (0.5 | ) | (1.4 | ) | (0.0 | ) | (0.4 | ) | (0.4 | ) | (1.5 | ) | (2.3 | ) | ||||||||||||
| Adjusted Net Earnings | $ | 21.9 | $ | 21.2 | $ | 27.7 | $ | 27.9 | $ | 98.6 | $ | 19.2 | $ | 20.3 | $ | 31.0 | $ | 27.0 | $ | 97.6 | |||||||||||
| Adjusted Diluted Earnings per share (4) | |||||||||||||||||||||||||||||||
| Diluted Earnings per share | $ | 0.40 | $ | 0.38 | $ | 0.41 | $ | 0.52 | $ | 1.70 | $ | 0.36 | $ | 0.31 | $ | 0.58 | $ | 0.47 | $ | 1.72 | |||||||||||
| Restructuring charges, net of tax effect | - | - | 0.09 | (0.01 | ) | 0.09 | - | 0.06 | - | (0.01 | ) | 0.05 | |||||||||||||||||||
| M&A charges, net of tax effect | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 | - | 0.02 | 0.03 | 0.06 | 0.10 | |||||||||||||||||||||
| Adjusted Diluted Earnings per share | $ | 0.40 | $ | 0.39 | $ | 0.51 | $ | 0.52 | $ | 1.81 | $ | 0.36 | $ | 0.39 | $ | 0.60 | $ | 0.53 | $ | 1.87 | |||||||||||
| Notes continued: | |||||||||||||||||||||||||||||||
| (4) Adjusted earnings and adjusted diluted earnings per share represent net earnings and diluted earnings per share per the Condensed Consolidated Statements of Earnings net of charges or credits for items to be highlighted for comparability purposes. These measures are not calculated based upon GAAP and should not be considered as an alternative to net earnings or diluted earnings per share or as an indicator of the Company's operating performance. However, this presentation is important to investors for understanding the operating results of | |||||||||||||||||||||||||||||||
| For all reconciliations of GAAP measures to Non-GAAP measures, the summation of the individual components may not equal the total due to rounding. | |||||||||||||||||||||||||||||||
Source: